Key result
Elevated Lp(a) is independently linked to higher short-term ASCVD risk.
Why the study?
Lipoprotein(a) is underutilized in short-term atherosclerotic cardiovascular disease risk prediction despite its potential prognostic value.
Does the inclusion of Lipoprotein(a) improve the prediction of short-term incident ASCVD events in machine learning models?
Cohort (n=785,913)
Does the inclusion of Lipoprotein(a) improve the prediction of short-term incident ASCVD events in machine learning models?
Elevated Lp(a) is a significant independent predictor of short-term ASCVD risk, and its inclusion improves machine learning risk prediction models.
Answers are grounded in this paper and cite their sources.
May support Lp(a) testing in short-term risk models; hypothesis-generating pending randomized confirmation.
BACKGROUND: Lipoprotein(a) [Lp(a)] is underutilized in short-term atherosclerotic cardiovascular disease (ASCVD) risk prediction. OBJECTIVES: This study investigates Lp(a) contribution to short-term ASCVD event prediction using contemporary real-world data and machine learning (ML). METHODS: A cohort of 731,983 individuals from a claims database was used to investigate the association of Lp(a) with incident ASCVD and all-cause mortality using Cox proportional hazards models. Novel ML models were developed to predict incident ASCVD events at 1, 2, and 3 years after Lp(a) testing. The models were validated in an independent cohort of 53,930 patients. RESULTS: An increase of 50 nmol/L in Lp(a) was independently associated with incident ASCVD events (HR: 1.072; 95% CI: 1.059-1.084) and all-cause mortality (HR: 1.041; 95% CI: 1.015-1.068) after adjustment for age, sex, and race/ethnicity. Novel ML models featuring Lp(a) predicted incident ASCVD events at 1, 2, and 3 years with robust discrimination (C-statistic: 0.83-0.84) in both the derivation and validation cohorts. Modest underestimation of risk was observed in the validation cohort for the 1-year model (calibration slope 1.25). Lp(a) contributed more to 1-year ASCVD prediction than smoking, diabetes, and other lipid parameters. Inclusion of Lp(a) in the 1-year model led to an integrated discrimination improvement of 0.03 and an optimal net reclassification improvement of 10% at a risk threshold of 26%. CONCLUSIONS: Lp(a) is a significant predictor of short-term ASCVD risk. Assessing Lp(a) and imminent ASCVD risk may assist in identifying patients who may benefit from escalation of preventative therapies.
No takes yet. Share an insight, caveat, or question.
Ward et al. (2025) conducted a cohort in atherosclerotic cardiovascular disease (ASCVD) (n=785,913). Lipoprotein(a) was evaluated on incident ASCVD events (HR 1.072, 95% CI 1.059-1.084). A 50 nmol/L increase in Lipoprotein(a) was independently associated with incident ASCVD events (HR 1.072; 95% CI 1.059-1.084) and all-cause mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: